As TGF-β ligand inhibition, FSTL3 knockdown negatively regulates activin expression, enhances downstream SMAD2 phosphorylation, and increases Bcl-2 expression, exerting a role in protecting cardiomyocytes and inhibiting cardiac hypertrophy. The gene discussed is SMAD2; the disease is cardiac hypertrophy.